The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats

Drug Metabolism Reviews

Volumn 46, Issue 2, 2014, Pages 128-141

  Simon, Lacey C ^a   Sabliov, Cristina M ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Biodistribution; Drug delivery; I.v. delivery; Metabolism; Oral delivery; Polymeric NPs

Indexed keywords

ETOPOSIDE; INDOCYANINE GREEN; LETROZOLE; PACLITAXEL; POLYGLACTIN; TETANUS TOXOID; THYMOPENTIN; DRUG CARRIER; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL MODEL; ARTICLE; BRAIN; DRUG DELIVERY SYSTEM; HEART; IN VIVO STUDY; KIDNEY; LIVER; LUNG; NONHUMAN; ORGAN SIZE; ORGAN WEIGHT; PARTICLE SIZE; SPLEEN; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; MOUSE; ORAL DRUG ADMINISTRATION; RAT; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; DRUG CARRIERS; LACTIC ACID; MICE; NANOPARTICLES; ORGAN SPECIFICITY; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84899445951     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.864664     Document Type: Article

References (23)

1. Acharya S, Sahoo SK. (2011). PLGA NPs containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63: 170-183.
2. Acharya G, Shin CS, Vedantham K, et al. (2010). A study of drug release from homogenous PLGA microstructures. J Control Release 146: 201-206.
3. Aggarwal P, Hall JB, McLeland CB, et al. (2009). NP interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61: 428-437.
4. Beletsi A, Panagi Z, Avgoustakis K. (2005). Biodistribution properties of NPs based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm 298: 233-241.
5. Brenner GM, Stevens CW. (2009). Pharmacology. Philadelphia (PA): Saunders Elzevier.
6. Cartiera MS, Johnson KM, Rajendran V, et al. (2009). The uptake and intracellular fate of PLGA NPs in epithelial cells. Biomaterials 30: 2790-2798.
7. Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based NPs: An overview of biomedical applications. J Control Release 161: 505-522.
8. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. (2011). The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems - A review. Int J Pharm 415: 34-52.
9. Gaumet M, Vargas A, Gurny R, Delie F. (2008). Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69: 1-9.
10. Li Y, Pei Y, Zhang X, et al. (2001). PEGylated PLGA NPs as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release 71: 203-211.
11. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. (2007). Estradiol loaded PLGA NPs for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119: 77-85.
12. Mondal N, Halder KK, Kamila MM, et al. (2010). Perparation, characterization, and biodistribution of letrozole loaded PLGA NPs in Ehrlich Ascites tumor bearing mice. Int J Pharm 397: 194-200.
13. Mouse Phenome Database. The Jackson Laboratory. [Online] Available from: http://phenome.jax.org/ [last accessed 4 March 2012].
14. Owens DE, Peppas NA. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric NPs. Int J Pharm 307: 93-102.
15. Parveen S, Sahoo SK. (2011). Long circulating chitosan/PEG blended PLGA NP for tumor drug delivery. Eur J Pharmacol 670: 372-383.
16. Phillips MA, Vargas A, Gran ML, Peppas NA. (2010). Targeted nanodelivery of drugs and diagnostics. Nanotoday 5: 143-159.
17. Rat Phenome Database [Online]. Available from: http://www.anim.med.kyoto- u.ac.jp/nbr/strainsx/ow-list.aspx [last accessed 4 March 2012].
18. Saxena V, Sadoqi M, Shao J. (2006). Polymeric nanoparticulate delivery system for indocyanine green: Biodistribution in healthy mice. Int J Pharm 308: 200-204.
19. Snehalatha M, Venugopal K, Saha RN, et al. (2008). Etoposide loaded PLGA and PCL NPs II: Biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv 15: 277-287.
20. Tobío M, Sánches A, Vila A, et al. (2000). The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surface B 18: 315-323.
21. Tosi G, Vergoni AV, Ruozi B, et al. (2010). Sialic acid and glycopeptides conjugated PLGA NPs for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 145: 49-57.
22. Vergoni AV, Tosi G, Tacchi R, et al. (2009). NPs as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine 5: 369-377.
23. Yin Y, Chen D, Qiao M, et al. (2007). Lectin-conjugated PLGA NPs loaded with thymopentin: Ex vivo bioadhesion and in vivo biodistribution. J Control Release 123: 27-38.